Dianthus posts interim Phase 3 data for claseprubart in rare nerve disorder

Dianthus Therapeutics disclosed interim clinical trial results for its lead drug candidate claseprubart, which is being tested as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting peripheral nerves. The company posted responder analysis data from the first 40 patients who completed Part A of its pivotal Phase 3 CAPTIVATE trial through an updated investor presentation on its website. For retail investors, this represents a meaningful clinical milestone as Phase 3 trials are the final stage before potential regulatory approval.

The choice to release interim data suggests the company may be seeing encouraging signals worth sharing with investors ahead of full trial readout. However, the filing provides no detail on the actual results—whether patients responded positively or negatively to treatment. Investors should watch for the company's next earnings call or investor presentation where management will likely discuss these interim findings in detail, including specific efficacy and safety metrics that will determine whether claseprubart advances toward FDA approval.